AU2017365158B2 - Cyclic dinucleotides as sting agonists - Google Patents

Cyclic dinucleotides as sting agonists Download PDF

Info

Publication number
AU2017365158B2
AU2017365158B2 AU2017365158A AU2017365158A AU2017365158B2 AU 2017365158 B2 AU2017365158 B2 AU 2017365158B2 AU 2017365158 A AU2017365158 A AU 2017365158A AU 2017365158 A AU2017365158 A AU 2017365158A AU 2017365158 B2 AU2017365158 B2 AU 2017365158B2
Authority
AU
Australia
Prior art keywords
compound
mmol
added
mixture
sting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017365158A
Other languages
English (en)
Other versions
AU2017365158A1 (en
Inventor
Leonid Beigelman
Gilles C. Bignan
Peter Connolly
James Patrick EDWARDS
Stuart Emanuel
Sylvie Laquerre
Mark Richter
Santhosh Kumar Thatikonda
Lu TIANBAO
Guangyi Wang
Minghong Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AU2017365158A1 publication Critical patent/AU2017365158A1/en
Application granted granted Critical
Publication of AU2017365158B2 publication Critical patent/AU2017365158B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2017365158A 2016-11-25 2017-11-21 Cyclic dinucleotides as sting agonists Ceased AU2017365158B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662426350P 2016-11-25 2016-11-25
US62/426,350 2016-11-25
US201762502983P 2017-05-08 2017-05-08
US62/502,983 2017-05-08
US201762555232P 2017-09-07 2017-09-07
US62/555,232 2017-09-07
PCT/US2017/062901 WO2018098203A1 (en) 2016-11-25 2017-11-21 Cyclic dinucleotides as sting agonists

Publications (2)

Publication Number Publication Date
AU2017365158A1 AU2017365158A1 (en) 2019-06-06
AU2017365158B2 true AU2017365158B2 (en) 2022-02-17

Family

ID=60937846

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017365158A Ceased AU2017365158B2 (en) 2016-11-25 2017-11-21 Cyclic dinucleotides as sting agonists

Country Status (13)

Country Link
US (2) US11472830B2 (enExample)
EP (1) EP3544989A1 (enExample)
JP (2) JP7316936B2 (enExample)
KR (1) KR20190085107A (enExample)
CN (1) CN110291096A (enExample)
AU (1) AU2017365158B2 (enExample)
BR (1) BR112019010606A2 (enExample)
CA (1) CA3044693A1 (enExample)
JO (1) JOP20170188A1 (enExample)
MX (1) MX2019006082A (enExample)
TW (1) TW201831192A (enExample)
UY (1) UY37495A (enExample)
WO (1) WO2018098203A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060396T2 (hu) 2016-03-18 2023-02-28 Immune Sensor Llc Ciklikus DI-nukleotid vegyületek és azok felhasználási módszerei
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CN117402852A (zh) 2016-10-14 2024-01-16 精密生物科学公司 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
US11021511B2 (en) * 2017-01-27 2021-06-01 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
JP7275031B2 (ja) * 2017-01-27 2023-05-17 ヤンセン バイオテツク，インコーポレーテツド Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
AU2018323053A1 (en) * 2017-08-30 2020-03-19 Beijing Xuanyi Pharmasciences Co., Ltd Cyclic di-nucleotides as stimulator of interferon genes modulators
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
KR20200098511A (ko) 2017-11-10 2020-08-20 다케다 야쿠힌 고교 가부시키가이샤 Sting 조절제 화합물, 및 제조 및 사용 방법
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
ES2962605T3 (es) 2018-02-26 2024-03-20 Gilead Sciences Inc Compuestos de pirrolizina sustituidos como inhibidores de la replicación del VHB
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
KR20210015937A (ko) 2018-06-01 2021-02-10 에자이 알앤드디 매니지먼트 가부시키가이샤 방광암을 치료하기 위한 방법
TW202030199A (zh) * 2018-07-17 2020-08-16 美商健生生物科技公司 作為ｓｔｉｎｇ促效劑之環狀二核苷酸
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CA3099904A1 (en) 2018-08-16 2020-02-20 Eisai R&D Management Co., Ltd. Salts of compounds and crystals thereof
KR20210081332A (ko) 2018-09-12 2021-07-01 실버백 테라퓨틱스, 인크. 면역 자극성 접합체를 사용한 질환의 치료를 위한 조성물
BR112021005208A2 (pt) 2018-09-21 2021-06-08 Shanghai De Novo Pharmatech Co., Ltd. análogo de dinucleotídeo cíclico, composição farmacêutica do mesmo, e aplicação
WO2020092127A1 (en) * 2018-10-29 2020-05-07 Venenum Biodesign, LLC Novel sting agonists
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
BR112021008255A2 (pt) 2018-10-31 2021-08-03 Gilead Sciences, Inc. compostos de 6-azabenzimidazol substituídos como inibidores de hpk1
JP7273172B2 (ja) 2018-10-31 2023-05-12 ギリアード サイエンシーズ， インコーポレイテッド Ｈｐｋ１阻害活性を有する置換６－アザベンゾイミダゾール化合物
WO2020135715A1 (zh) * 2018-12-29 2020-07-02 上海济煜医药科技有限公司 作为肿瘤免疫类的化合物及其应用
US12318403B2 (en) 2019-03-07 2025-06-03 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides and prodrugs thereof
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
CN109929894B (zh) * 2019-04-17 2021-06-01 中国农业科学院兰州兽医研究所 一种猪源第二信使分子2′3′-cGAMP的制备及活性鉴定方法
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
JP7621974B2 (ja) 2019-05-09 2025-01-27 アリゴス セラピューティクス インコーポレイテッド Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物
CN114173824A (zh) 2019-05-10 2022-03-11 武田药品工业株式会社 抗体药物缀合物
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
CA3145889A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
IL315295A (en) 2019-09-30 2024-10-01 Gilead Sciences Inc Hbv vaccines and methods treating hbv
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
JPWO2021206158A1 (enExample) 2020-04-10 2021-10-14
US20230226218A1 (en) 2020-05-11 2023-07-20 Erytech Pharma Red Cell Extracellular Vesicles (RCEVs) Containing Cargoes and Methods of Use and Production Thereof
CA3183993A1 (en) 2020-07-01 2022-01-06 Peter R. Baum Anti-asgr1 antibody conjugates and uses thereof
EP4192474B1 (en) 2020-08-07 2025-09-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
US20230256109A1 (en) 2020-08-07 2023-08-17 Tambo, Inc. Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy
WO2022083584A1 (zh) * 2020-10-20 2022-04-28 泰励生物科技（上海）有限公司 多功能环二核苷酸及其用途
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
TW202310852A (zh) 2021-05-13 2023-03-16 美商基利科學股份有限公司 ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CR20230585A (es) 2021-06-23 2024-02-19 Gilead Sciences Inc Compuestos Moduladores de Diacilglicerol Quinasa.
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2025007108A2 (en) * 2023-06-30 2025-01-02 Immunogenesis, Inc. Compositions comprising sting agonists and methods of use for treating glioma
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140341976A1 (en) * 2013-05-18 2014-11-20 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" -dependent signalling
WO2014189805A1 (en) * 2013-05-18 2014-11-27 Auro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
US20150343056A1 (en) * 2012-12-19 2015-12-03 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
WO2016120305A1 (en) * 2015-01-29 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Cyclic dinucleotides useful for the treatment of inter alia cancer
WO2017027646A1 (en) * 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2017075477A1 (en) * 2015-10-28 2017-05-04 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2017093933A1 (en) * 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060167241A1 (en) * 2003-07-15 2006-07-27 Mitsui Chemicals, Inc. Method for synthesizing cyclic bisdinucleoside
MX374828B (es) * 2013-04-29 2025-03-06 Memorial Sloan Kettering Cancer Center Composiciones y metodos para alterar la señalizacion del segundo mensajero.
HK1223794A1 (zh) 2013-10-21 2017-08-11 德雷克塞尔大学 治疗慢性乙型肝炎病毒感染的sting激动剂的用途
PL3233882T3 (pl) * 2014-12-16 2020-04-30 Kayla Therapeutics Fluorowane cykliczne dinukleotydy do indukcji cytokin
AU2015362773B2 (en) 2014-12-17 2019-01-03 Lipogen Llc Method of treating cancer with cGAMP or cGAsMP
HUE060396T2 (hu) 2016-03-18 2023-02-28 Immune Sensor Llc Ciklikus DI-nukleotid vegyületek és azok felhasználási módszerei

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150343056A1 (en) * 2012-12-19 2015-12-03 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
US20140341976A1 (en) * 2013-05-18 2014-11-20 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" -dependent signalling
WO2014189805A1 (en) * 2013-05-18 2014-11-27 Auro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2016120305A1 (en) * 2015-01-29 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Cyclic dinucleotides useful for the treatment of inter alia cancer
WO2017027646A1 (en) * 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2017075477A1 (en) * 2015-10-28 2017-05-04 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2017093933A1 (en) * 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting

Also Published As

Publication number Publication date
TW201831192A (zh) 2018-09-01
US20180162899A1 (en) 2018-06-14
UY37495A (es) 2018-05-31
CN110291096A (zh) 2019-09-27
US11472830B2 (en) 2022-10-18
JP2022110131A (ja) 2022-07-28
KR20190085107A (ko) 2019-07-17
JP7316936B2 (ja) 2023-07-28
US20230144627A1 (en) 2023-05-11
JOP20170188A1 (ar) 2019-01-30
BR112019010606A2 (pt) 2019-09-17
JP2020500862A (ja) 2020-01-16
CA3044693A1 (en) 2018-05-31
WO2018098203A1 (en) 2018-05-31
EP3544989A1 (en) 2019-10-02
AU2017365158A1 (en) 2019-06-06
MX2019006082A (es) 2019-11-12

Similar Documents

Publication Publication Date Title
AU2017365158B2 (en) Cyclic dinucleotides as sting agonists
EP3573718B1 (en) Cyclic dinucleotides as sting agonists
AU2018212787B2 (en) Cyclic dinucleotides as sting agonists
EP3724205B1 (en) Cyclic dinucleotides as sting agonists
US20230287034A1 (en) Cyclic dinucleotides as sting agonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired